

## NOTICE OF CHANGE IN CORPORATE STRUCTURE

Pursuant to Section 4.9 of National Instrument 51-102

Continuous Disclosure Obligations

### Item 1 Names of the Parties to the Transaction

The following companies were parties to the transaction:

- Awakn Life Sciences Corp. (formerly 1169082 B.C. Ltd.), a reporting issuer incorporated under the *Business Corporations Act* (British Columbia) (the “**Company**”)
- Awakn Life Sciences Inc., a private company incorporated under the *Business Corporations Act* (Ontario) (“**Awakn**”)
- 2835517 Ontario Ltd., a wholly owned subsidiary of the Company incorporated under the *Business Corporations Act* (Ontario) (“**Subco**”)

### Item 2 Description of the Transaction

#### Reverse Take-Over Transaction

On June 16, 2021, the Company completed a reverse takeover transaction with Awakn (the “**Transaction**”). The Transaction was completed in accordance with an amalgamation agreement dated May 13, 2021 (the “**Amalgamation Agreement**”) among the Company, Subco, and Awakn.

In accordance with the Amalgamation Agreement, effective as of June 15, 2021, the Company changed its name from 1169082 B.C. Ltd. to Awakn Life Sciences Corp. (the “**Name Change**”) and consolidated its issued and outstanding shares on the basis of one (1) post-consolidation share for every 42.5105 pre-consolidation shares (the “**Consolidation**”). Effective June 16, 2021 the Company completed the Transaction, pursuant to which Subco amalgamated with Awakn to form a single, wholly-owned subsidiary of the Company. Shareholders of Awakn received one (1) post-Consolidation common share of the Company for each common share of Awakn, and outstanding convertible securities of Awakn were exchanged for convertible securities of the Company on substantially the same terms.

The Company continues to be a reporting issuer in British Columbia, Alberta, and, based on its common shares being listed on Neo Exchange Inc. effective June 23, 2021, has become a reporting issuer in Ontario. The Company is a “non-venture issuer” as such term is defined in National Instrument 51-102. The Company’s financial year end was May 31, however, pursuant to the Transaction, the Company has adopted Awakn’s financial year end of January 31.

### Item 3 Effective Date of the Transaction

The effective date of the Transaction was June 16, 2021.

**Item 4 Name of each Party, if any, that ceased to be a Reporting Issuer after the Transaction and of each Continuing Entity**

Not applicable.

**Item 5 Date of the Reporting Issuer's First financial Year-End after the Transaction, if applicable**

The Company's first financial year end subsequent to the Transaction will be January 31, 2022

**Item 6 Periods for filing Interim and Annual Financial Statements after the Transaction**

The Company will file:

- Unaudited financial statements of Awakn for the three months ended April 30, 2021, pursuant to s.4.10(2);
- Audited annual financial statements of the Company for the year financial year ended May 31, 2021 (pre-Transaction);
- Unaudited financial statements of the Company for the six months ended July 31, 2021 (post-Transaction);
- Unaudited financial statements of the Company for the nine months ended October 31, 2021 (post-Transaction);
- Audited financial statements of the Company for the financial year ended January 31, 2022 (post-Transaction).

**Item 7 Documents filed under NI 51-102 that describe the Transaction**

In connection with the Transaction, the Company filed the following documents which are available under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com):

March 4, 2021	News Release
May 17, 2021	News Release
May 21, 2021	Notice of Annual General and Special Meeting of Shareholders
May 21, 2021	Joint Information Circular
May 25, 2021	Material Change Report
May 25, 2021	Amalgamation Agreement
June 8, 2021	News Release
June 17, 2021	News Release
June 21, 2021	Material Change Report

**DATED: June 25, 2021.**